Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹27,932.0 Cr -3.4% 1.4% -0.6% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹386,905.0 Cr -5.2% -7.6% -8.6% Stock Analytics
DIVIS LABORATORIES ₹159,357.0 Cr -5.6% -7.3% 1.5% Stock Analytics
TORRENT PHARMACEUTICALS ₹134,788.0 Cr -0.6% 4.8% 25% Stock Analytics
CIPLA ₹110,628.0 Cr -4.5% -9.7% -4.6% Stock Analytics
DR REDDYS LABORATORIES ₹96,441.5 Cr -2.6% -9.7% -10.5% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-3.4%

1.4%

-0.6%

SENSEX

-2.1%

-3%

6.8%


You may also like the below Video Courses